Applied Genetic Technologies Corporation (AGTC)

Etorro trading 970x250
Applied Genetic Technologies Corporation (AGTC) Logo

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida. Address: 14193 NW 119th Terrace, Alachua, FL, United States, 32615

Applied Genetic Technologies Corporation News and around…

Latest news about Applied Genetic Technologies Corporation (AGTC) common stock and company :

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
11 Jan, 2022 Yahoo! Finance

Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of r

AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference
04 Jan, 2022 Yahoo! Finance

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, and Susan Schneider M.D., Chief Medical Office

The Math Shows ITOT Can Go To $117
13 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors
06 Dec, 2021 Yahoo! Finance

Robinson’s expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management teamGAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited re

These 2 Penny Stocks Could Surge Over 400%, Says Wells Fargo
17 Nov, 2021 Yahoo! Finance

The rapid rise in the stock market has investors in buying mood. Rising stocks are offering the best returns in today’s climate of ultra-low interest rates, and if investors choose carefully, they can find stocks that are poised to beat the increasing rate of inflation as well. And that will bring us to penny stocks. For any investor seeking the best returns, the ‘pennies’ are a natural place to look. Traditionally stocks sold at prices lower than one dollar, penny stocks these days are consider

AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer
16 Nov, 2021 Yahoo! Finance

With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC’s preclinical pipeline GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-

AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
12 Nov, 2021 Yahoo! Finance

- Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) -GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the presentation of additional analyses and conclu

AGTC Appoints Hope D’Oyley-Gay as General Counsel
11 Nov, 2021 Yahoo! Finance

Ms. D’Oyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment

Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 Nov, 2021 Yahoo! Finance

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022Initiating clinical safety evaluation of higher dosing for OTO-413 to support full dose-ranging Phase 2 efficacy trial expected to start by the end of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN D

AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference
10 Nov, 2021 Yahoo! Finance

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 10:4

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
09 Nov, 2021 Yahoo! Finance

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021
09 Nov, 2021 Yahoo! Finance

-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced financ

AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021
02 Nov, 2021 Yahoo! Finance

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021. AGTC management will host a conference call beginning a

AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
19 Oct, 2021 Yahoo! Finance

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021. Ms. Washer will disc

AGTC Announces Two Key Leadership Team Appointments
14 Oct, 2021 Yahoo! Finance

- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Susan Schneider, M.D., as Chief

AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
12 Oct, 2021 Yahoo! Finance

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021. Ms. Washer will provide a corporat

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

AGTC to Present at Upcoming Cell & Gene Management Meeting on the Mesa
12 Oct, 2021 Yahoo! Finance

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Management Meeting on the Mesa being held October 12-14, 2021. Ms. Washer will provide

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
28 Sep, 2021 FinancialContent

Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
27 Sep, 2021 FinancialContent
Applied Genetic: Q4 Earnings Insights
27 Sep, 2021 FinancialContent

Applied Genetic(NASDAQ:AGTC) stock fell by 5.56% on Friday after the company reported its Q4 earnings results on Thursday, ...

Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
24 Sep, 2021 FinancialContent

After escalating the dose in its pediatric gene therapy trial,Applied Genetic Technologies Corporation(NASDAQ: AGTC) has ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
24 Sep, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) stock moved upwards by 251.16% to $21.07 during Friday's pre-market ...

Applied Genetic Technologies Corporation (AGTC) is a NASDAQ Common Stock listed in , ,

970x250